🟢 Amneal Pharmaceuticals is trading 10.1% up today after beating Q2 expectations and raising full-year 2026 guidance

Amneal Pharmaceuticals is trading 10.1% up at $21.02 following a strong Q2 2026 earnings report and an upward revision to its annual outlook.

• The company delivered 10% revenue growth and exceeded EPS expectations, fueled by a strategic pivot toward higher-margin specialty and biosimilar segments.
• Management raised full-year 2026 revenue and EBITDA guidance, signaling strong momentum and lifting investor demand.